INSERM U773/CRB3, Université Paris-Diderot, Paris, France.
Clin Liver Dis. 2013 Aug;17(3):399-412. doi: 10.1016/j.cld.2013.05.006. Epub 2013 Jun 27.
There is a growing interest in serum HBsAg quantification (qHbsAg). HBsAg titers are negatively correlated with liver fibrosis in HBeAg(+) patients. In HBeAg(-) HBsAg level <1000 IU/ml and HBV-DNA titer <2000 IU/ml accurately identify inactive carriers. During PEG-IFN treatment qHBsAg identifies patients with no benefit from therapy at week 12, allowing stopping or switched- "week 12 stopping rule". During nucleos(t)ide analogues the role of qHBsAg need to be clarified. In clinical practice qHBsAg is a simple and reproducible tool that may be used in association with HBV-DNA to classify patients during the natural history of HBV and to monitor therapy.
人们对血清 HBsAg 定量（qHbsAg）越来越感兴趣。在 HBeAg(+)患者中，HBsAg 滴度与肝纤维化呈负相关。在 HBeAg(-)患者中，HBsAg 水平<1000IU/ml 和 HBV-DNA 载量<2000IU/ml 可准确识别非活动携带者。在 PEG-IFN 治疗期间，qHBsAg 可在第 12 周识别出无治疗获益的患者，从而允许停药或转换治疗-“第 12 周停药规则”。在核苷（酸）类似物中，需要明确 qHBsAg 的作用。在临床实践中，qHBsAg 是一种简单且可重复的工具，可与 HBV-DNA 联合使用，用于在 HBV 的自然史中对患者进行分类，并监测治疗。
